Web10 dic 2024 · PCI: weight-based dosing, ACT CPB †: ACT >2.5 times baseline Non-CPB †: ACT >300 s Prolonged half-life in patients with renal impairment Avoid stasis in the CPB circuit Hypothermia should be minimized to avoid drug accumulation Argatroban Direct thrombin inhibitor 39-51 min (normal hepatic function) 181 min (hepatic impairment) WebArgatroban is a a small molecule, synthetic direct thrombin inhibitor. It is used as an alternative anticoagulant in patients with heparin-induced thrombocytopenia (HIT). It has a relatively short half life of 40-50 minutes and is eliminated by hepatic metabolism and biliary secretion. There are no specific guidelines for dosing in
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
Web16 nov 2004 · Argatroban is metabolized in the liver by hydroxylation and aromatization and requires dosage adjustment in patients with moderate hepatic impairment defined as a Child-Pugh score >6. The normal recommended starting dose of 2 mcg/kg/min is reduced to 0.5 mcg/kg/min in these patients. Objective: Our clinical observation was that the … WebArgatroban – There are very limited data for use of argatroban during cardiac surgery requiring CPB . Catastrophic intraoperative bleeding has been reported in some patients … shone in hebrew
Argatroban for anticoagulation during cardiac surgery - PubMed
WebWe retrospectively evaluated argatroban dosing patterns, clinical outcomes, and the effects of heart failure and multiple organ system failure on dosing requirements in 65 adult, intensive care patients administered argatroban anticoagulation for clinically suspected heparin-induced thrombocytopenia (n=56) or history of heparin-induced … WebArgatroban is a parenteral direct thrombin inhibitor that requires close monitoring to ensure safety and efficacy. Limited data exist to describe its effect in critically ill patients. This was a retrospective, single-center, cohort study that aimed to compare argatroban dosing requirements in those … Web3 apr 2024 · If the PTT is elevated at baseline and this is unrecognized, it may lead to sub-therapeutic argatroban dosing (“PTT confounding”). If the PTT is reduced at baseline, this could lead to problems with argatroban pseudo-resistance (discussed below). The optimal target PTT might be 1.5-3 times the baseline value. shone ice cave